Full Text View
Tabular View
No Study Results Posted
Related Studies
Octreotide Efficacy and Safety in First-Line Acromegalic Patients
This study has been suspended.
Study NCT00171886.   Last updated on August 17, 2006.
Information provided by Novartis
Related Studies can be found by searching for the Conditions, Interventions, and Sponsors found in this study:
Conditions listed in this trial
Acromegaly
More general conditions related to this trial
Bone Diseases
Bone Diseases, Endocrine
Brain Diseases
Central Nervous System Diseases
Endocrine System Diseases
Hyperpituitarism
Hypothalamic Diseases
Musculoskeletal Diseases
Nervous System Diseases
Pituitary Diseases
Interventions listed in this trial
Octreotide
More general drug interventions related to this trial
Antineoplastic Agents
Antineoplastic Agents, Hormonal
Gastrointestinal Agents
Pharmacologic Actions
Therapeutic Uses
Sponsors listed in this trial
Novartis
None


U.S. National Library of Medicine,  Contact Help Desk
U.S. National Institutes of Health,  U.S. Department of Health & Human Services,
USA.gov,  Copyright,  Privacy,  Accessibility,  Freedom of Information Act

U.S. National Institutes of Health U.S. National Library of Medicine U.S. Department of Health & Human Services